CMLT

Definitive Agreement

EQRx, Inc.

CM Life Sciences III Inc.

Raised
$552M
CIK
1843762
Focus
Life Sciences, Biotech
External link: SEC Filings

SPAC Team

Leadership

Eli Casdin has been our Chief Executive Officer since January 2021. He founded Casdin Capital, LLC, an investment firm focused on the life sciences and healthcare industry, in November 2011 and currently serves as its Chief Investment Officer. Since July 2020 and December 2020, he also serves as the Chief Executive Officer of CM Life Sciences, Inc. (Nasdaq: CMLF) and CM Life Sciences II Inc., respectively, both blank check companies. Mr. Casdin has served on the boards of directors of CM Life Sciences, Inc. and CM Life Sciences II Inc., since July 2020 and December 2020, respectively. Mr. Casdin holds a B.S. degree from Columbia University School of General Studies and an MBA from Columbia Business School. His qualifications to serve on our board of directors include his extensive leadership experience as an executive officer of an investment firm, his extensive public and private company directorship experience in the life sciences and healthcare sectors, and his expertise in finance, capital markets, and the biotechnology industry.

Keith Meister has been Chairman of our board of directors since January 2021. He founded Corvex Management LP, a New York based investment manager, in December 2010 and since its inception has served as its Managing Partner and Chief Investment Officer. From 2003 to 2010, Mr. Meister served as Chief Executive Officer and then Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises L.P. (Nasdaq: IEP), the primary investment vehicle for Carl Icahn. Mr. Meister currently serves on the board of directors of MGM Resorts International (NYSE: MGM), a global hospitality and entertainment company, and its affiliate Roar Digital. Mr. Meister also serves as Chairman of the boards of directors of CM Life Sciences, Inc. and CM Life Sciences II Inc. Mr. Meister has previously served on the Board of Directors of numerous other public companies in his career, including Yum! Brands Inc. (NYSE: YUM), The Williams Companies, Inc. (NYSE: WMB), ADT, Inc. (NYSE: ADT), Ralcorp Holdings, Inc. and Motorola, Inc. (now Motorola Solutions, Inc., NYSE: MSI/Motorola Mobility, Inc.). He is Chairman of the board of the Harlem Children’s Zone and also serves on the board of trustees of the American Museum of Natural History. Mr. Meister holds a B.A. degree in government from Harvard College where he graduated cum laude. His qualifications to serve on our board of directors include his extensive leadership experience as managing partner and executive officer of an investment firm and a diversified holding company, his extensive public company directorship experience in a variety of industries, and his expertise in finance, capital markets, strategic development, and risk management.

Brian Emes has been our Chief Financial Officer and Secretary since January 2021. Mr. Emes is also the Chief Financial Officer of Corvex Management LP, a New York based investment manager, which he joined in January 2013, and the Chief Financial Officer of CM Life Sciences, Inc. and CM Life Sciences II Inc., since July 2020 and December 2020, respectively. Mr. Emes holds a B.S. degree in finance and marketing from Elon University’s Martha & Spencer Love School of Business, and is a licensed certified public accountant.

Shaun Rodriguez has been our Chief Strategy Officer since January 2021. Mr. Rodriguez joined Casdin Capital, LLC, an investment firm focused on the life sciences and healthcare industry, in July 2015 as a Senior Research Analyst and currently serves as its Director of Life Science Research. His coverage universe at Casdin Capital, LLC focuses on life science tools, diagnostics, health technology and services, and industrial applications of biotechnology. Mr. Rodriguez also serves as Chief Strategy Officer of CM Life Sciences, Inc. and CM Life Sciences II Inc., since July 2020 and December 2020, respectively. From February 2011 to July 2015, Mr. Rodriguez served as Director and Senior Research Analyst in the healthcare equity research group of Cowen Inc. (Nasdaq: COWN), an investment bank and financial services company. Mr. Rodriguez holds a Ph.D. in biological sciences from Harvard University.

Christian Henry will serve on our board of directors following completion of this offering. Mr. Henry is Chairman of the Board of Pacific Biosciences of California, Inc. (Nasdaq: PACB), since 2020, Chairman of the Board of WAVE Life Sciences Ltd. (Nasdaq: WVE), since October 2017, and a director of Gingko Bioworks. Mr. Henry previously served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. (Nasdaq: ILMN), an applied genomics technology company, from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina. Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc., an online ticket provider, from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry holds a B.A. in biochemistry and cell biology from the University of California, San Diego and an M.B.A., with a concentration in finance, from the University of California, Irvine. His qualifications to serve on our board of directors include his wealth of leadership experience in the life sciences industry and his strengths in corporate strategy, finance and operations.

Kwame Owusu-Kesse will serve on our board of directors following completion of this offering. Mr. Owusu-Kesse is Chief Executive Officer of Harlem Children’s Zone, an anti-poverty non-profit organization, since July 2020, and previously served as Harlem Children’s Zone’s Chief Operating Officer from June 2014 to June 2020 and Senior Manager from July 2012 to June 2014. Prior to Harlem Children’s Zone, Mr. Owusu-Kesse worked as an investment banking analyst at Morgan Stanley, multinational investment bank and financial services company. Mr. Owusu-Kesse received a B.A. in economics from Harvard College, an M.B.A. from Harvard Business School, and a master’s in public policy from Harvard Kennedy School. His qualifications to serve on our board of directors include his leadership experience across private, public, and social domains and his demonstrated expertise in cross-disciplinary management and financial analysis.

Chad Robins will serve on our board of directors following completion of this offering. Mr. Robins is Chief Executive Officer, Co-Founder and Chairman of Adaptive Biotechnologies Corp. (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, since 2009. In addition to serving as Chairman of the Board for Adaptive Biotechnologies Corp., he also holds board positions with AltPep Corporation, AdvaMedDx, and HeadLight Technologies, Inc. Mr. Robins also serves on the executive board of Life Science Washington and the steering committee of the Coalition for 21st Century Medicine. Prior to Adaptive Biotechnologies Corp., Mr. Robins held executive-level positions in medical technology, investment and real estate companies. Mr. Robins holds an M.B.A. from The Wharton School at the University of Pennsylvania and a B.S. in Managerial Economics from Cornell University. His qualifications to serve on our board of directors include his executive leadership experience in the biotechnology industry.

Harlan Robins will serve on our board of directors following completion of this offering. Dr. Robins is Chief Scientific Officer and Co-Founder of Adaptive Biotechnologies Corp. (Nasdaq: ADPT), since 2009. Prior to co-founding Adaptive Biotechnologies Corp., Harlan served in various roles in the Computational Biology Program at Fred Hutchinson Cancer Research Center, a cancer research institute, including as an Assistant Faculty Member from 2006 to 2011, as an Associate from 2011 to April 2016, and as a Full Member and the Head of the program from April 2016 to June 2019. Dr. Robins holds a B.S. in Physics from Harvard University and a Master’s degree and Ph.D. in Physics from the University of California, Berkeley, with a visiting appointment to the California Institute of Technology. Harlan received postdoctoral appointments in the particle theory group at the Weizmann Institute of Science in Israel and at the Institute for Advanced Study in Princeton, NJ. His qualifications to serve on our board of directors include his scientific expertise and experience co-founding a biotechnology company.